(Rac)-Indoximod(Cat No.:I045304)is the racemic form of an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor used in cancer immunotherapy research. By modulating tryptophan metabolism and blocking the immunosuppressive effects of kynurenine accumulation, it helps restore T-cell activation and enhance antitumor immune responses. The racemic mixture contains both enantiomers, enabling comprehensive evaluation of biological activity and pharmacokinetics. (Rac)-Indoximod has been studied in combination with immune checkpoint inhibitors, chemotherapy, and vaccines to improve therapeutic efficacy. It serves as a valuable tool for investigating immune regulation and developing novel strategies to overcome tumor-induced immune suppression.